Markets · Brief

Wegovy Cut BMI by 13.5% in Trial of Children Aged 6–11

Average BMI rose 2.7% with placebo over 68 weeks. The weekly injection is approved in the United States for obesity from age 12.

A child’s sneaker, a height gauge and a capped injection pen in a pediatric exam room.
AI-generated illustration: Kunkafa

Kunkafa News · Published · 2 min read

Kareem FaridBy Discuss with the author on X

Key points

  • The trial enrolled 167 children with obesity. Both groups received support with diet and physical activity.
  • At week 68, 38.4% of the Wegovy group fell below the obesity threshold, compared with 2.1% on placebo.

Children aged 6 to 11 with obesity who were assigned to Wegovy saw their body mass index fall 13.5% on average over 68 weeks, while BMI rose 2.7% in the placebo group. Novo Nordisk presented the phase 3 results on Monday at ObesityWeek in Washington. The main analysis included children who stopped treatment [1].

Researchers randomly assigned 112 children to weekly semaglutide, the ingredient in Wegovy, and 55 to placebo. A separate analysis estimated that if all participants had stayed on treatment, BMI would have fallen 17.4% with Wegovy and risen 2.2% with placebo [1].

Novo reported no unexpected safety concerns and no concerns about growth or puberty during the two-year study. Whether the benefit lasts into adulthood remains unknown, Novo medical director Andrea Traina told CNBC [1] [2]. In the U.S., Wegovy injections are approved for children aged 12 and older with obesity. The label lists nausea and vomiting as common side effects. Use below age 12 remains investigational [3].

Sources: [1] Novo Nordisk, November 16 · [2] CNBC, November 16 · [3] U.S. FDA, 2026 Wegovy label.

Kunkafa forecasts

S&P 500 Index

How far it could move, which way, by when, and how confident Kunkafa is.

Check the latest forecasts

More in Markets

From the Blog

All articles